‘Verzenio’, which faced difficulties in expanding its reimbursement standards last year, is now drawing attention to see if it will pass the review this time.

According to industry sources, Lily Korea’s CDK4/6 inhibitor Verzenio (abemaciclib) is expected to be considered for the Health Insurance Review and Assessment Service (HIRA)’s Cancer Disease Review Committee on the 31st. Their second attempt to expand the reimbursement is for Verzenio’s indication in early-stage breast cancer.

Verzenio faced challenges in initial attempt to expand its indication for early-stage breast cancer when it was presented to the Cancer Disease Review Committee. Despite submitting the applicat